Wegovy and a Fast Heart Rate: What the Evidence Says

What actually happens to heart rate on semaglutide — and why

GLP-1 receptor agonists, including semaglutide, act on receptors found not only in the gut but in cardiac tissue. The precise mechanism behind the heart-rate increase is still being studied, but the leading explanation is a mild sympathetic nervous system effect that nudges the resting pulse upward. In the STEP 1 trial, published in the New England Journal of Medicine, participants on 2.4mg semaglutide showed a mean increase of roughly 1–2 beats per minute over 68 weeks compared to placebo, statistically present but modest at the group level.

At the individual level, the picture varies. Some people notice nothing. Others describe a sense of their heart working faster, particularly in the hours after an injection or when a dose has just been increased. If you want to understand how semaglutide interacts with heart rate across the full dose range, including what the evidence shows at each stage of treatment, our dedicated guide covers the detail. The newer 7.2mg maintenance dose, approved by the MHRA in 2026, has not yet accumulated the same long-term trial dataset as 2.4mg, so individual monitoring remains prudent at higher doses.

For a fuller technical breakdown, the overview of how Wegovy affects heart rate covers the physiology in more depth. If you are specifically asking whether Wegovy causes a fast heart rate and what sits behind that effect, our dedicated page addresses the question directly. The short version: a small, persistent rise is within the documented profile of the medicine; a sudden, large, or symptomatic rise is a different signal entirely.

When a fast heart rate on Wegovy needs medical attention today

This is the decision that matters most. A resting pulse that sits a few beats higher than usual, with no other symptoms, in someone who is otherwise feeling fine, is unlikely to require emergency care. It is still worth logging and mentioning at your next clinical review.

The following patterns are different and need prompt attention:

• Heart rate persistently above 100 beats per minute at rest, with no obvious cause such as fever or exertion.
• Palpitations with chest tightness, pain, or pressure.
• Breathlessness, dizziness, or near-fainting at the same time as a fast heartbeat.
• A sudden, dramatic change from your normal baseline that feels new or alarming.

If any of the above apply, contact NHS 111 or go to your nearest urgent care centre. Do not stop taking Wegovy abruptly without clinical advice first (stopping suddenly is not recommended) but do make contact the same day. If you are experiencing a notably elevated heart rate on Wegovy and want to understand what counts as high, what typically drives it, and when to act, that page walks through each scenario clearly. Nausea, vomiting, or simply drinking less because food is less appealing can reduce circulating blood volume enough to trigger a compensatory increase in heart rate. Staying well hydrated throughout treatment reduces this risk considerably.

The role of your prescriber and what to bring to the conversation

A fast heart rate on Wegovy is not automatically a reason to stop treatment, but it is a clinical finding that your prescriber needs to know about. Before your next review, it helps to have some observations ready: your resting heart rate at different times of day (most smartphones have this via a health app, or you can count manually), when the fast rate tends to occur, how long it lasts, and whether anything reliably triggers or relieves it.

If you are a patient transferring from another service or requesting a dose increase, our clinical team reviews that information as part of the assessment, not as a formality but as a genuine clinical check. Heart rate is one of the things a prescriber weighs when deciding whether a dose increase is appropriate at a given point in treatment.

There is also a cardiovascular dimension worth knowing. Our guide on whether and how Wegovy affects heart rate addresses this directly, including the SELECT trial finding that semaglutide reduced the risk of major cardiovascular events in eligible adults despite the modest pulse increase, so the two effects are not simply in opposition. The NHS semaglutide medicines page sets out the recognised side effects and when to seek help, and is worth bookmarking for reference.

Continuing, pausing, or changing treatment, framing the choice

For most people, a mild increase in heart rate during Wegovy treatment is a known, manageable effect rather than a reason to discontinue. Pausing treatment is a clinical decision, not a personal one to make unilaterally, stopping and restarting can itself cause side effects to resurface and disrupts the therapeutic effect on appetite and weight.

The more useful frame is: document what you are experiencing, keep your prescriber informed, and let the clinical review process do its job. If you are looking at treatment options more broadly, the weight-loss treatment overview explains how semaglutide fits alongside other licensed options. If cost is a consideration while you are thinking this through, the Wegovy pricing page explains what a legitimate private prescription actually covers, including clinical review and aftercare, not just the medicine itself.

And if you have not yet started treatment but are weighing whether Wegovy is right for your situation, a free consultation with a GPhC-registered prescriber at nume (sorry, at nume) is the right starting point. Your medical history, including any cardiac history, is part of what the prescriber considers before anything is approved.